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Case Report
Transient visual loss with methotrexate, leucovorin chemotherapy for gestational 
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Gestational trophoblastic disease (GTD) is a disease of the proliferative trophoblastic allograft [1]. After uterine evacuation, 80% of hydatidiform mole cases follow 
spontaneous remission, while 20% progresses to post-molar 
gestational trophoblastic neoplasm (GTN) [1]. It is more common 
in some parts of Asia, with reported incidence rates as high as 2 
per 1000 pregnancies while the European and North American 
incidence is usually reported to be <1 per 1000 pregnancies [2]. 
Chemotherapy (CT) is an essential component of the management 
of GTN. For low-risk patients, single-agent methotrexate (MTX) 
or actinomycin-D has been reported to have remission rates of 
50–90% [3].
MTX is an antifolate drug which inhibits cell division by 
interfering with deoxyribonucleic acid replication [4]. The 
major toxicity is that of hematological, gastrointestinal, and 
dermatological systems due to the high turnover of cells [5]. 
Ocular toxicity with high-dose MTX occurs in almost 25% of 
patients and manifests as periorbital edema, ocular pain, blurred 
vision, photophobia, conjunctivitis, blepharitis, and decreased 
reflex tear. We report the case of a rare occurrence of sudden 
blurring of vision with self-remission in two consecutive courses 
of low-dose MTX CT for GTN.
CASE REPORT
A 24-year-old female presented to the department of radiation 
oncology with a history of abortion and profuse vaginal bleeding. 
She was fit for her age and had no associated comorbidity. The 
patient had a history of an uneventful pregnancy 2 years back. 
However, the subsequent pregnancy ended with a spontaneous 
abortion. She developed profuse vaginal bleeding for which she 
underwent dilatation and curettage (D and C) on three occasions, 
but to no relief. The fourth D and C included proper tissue 
sampling and the histopathological report revealed GTD (Fig. 1). 
From here, the patient was referred to our department for adjuvant 
treatment.
At presentation, she was in a good general condition with no 
systemic abnormalities/comorbidities and an Eastern Cooperative 
Oncology Group performance score of 1. Her general examination 
revealed normal range of vital parameters and no abnormality 
was detected on detailed systemic examination.
Her hemoglobin was 11.0 g%, total leukocyte count was 9700 
and platelet count was 210,000/mm3. Her β-human chorionic 
gonadotropin (HCG) value was 72,605 mIU/mL. She was 
stratified as a case of low-risk GTN (age < 40 years, antecedent 
abortion, no metastases or prior CT) and planned for single-agent 
CT with injection MTX (1 mg/kg) intramuscular alternating with 
injection leucovorin (0.1 mg/kg) intravenous for an 8-day cycle.
The patient received three courses of the planned CT 
uneventfully. However, during the fourth cycle, day 2 of CT 
(leucovorin), she had a sudden onset diminution of vision in both 
the eyes. The CT was withheld but after 20–30 min her vision 
became normal. The patient’s case sheet was reviewed for any 
associated medication, proper premedication as well as the CT 
drug batch/brand was checked but revealed no notable finding. 
She was thereafter advised for an ophthalmic consultation and a 
retinal examination revealed signs of early papilledema with mild 
hyperemic disc and obliterated cup but no major abnormality. 
A further exhaustive history regarding any visual problems 
revealed no previous episode of sudden/gradual blurring of 
vision. She was continued with her CT and completed the course 
uneventfully.
ABSTRACT
Methotrexate chemotherapy (CT) is a standard for low-risk gestational trophoblastic neoplasia. Its use is associated with minimal 
toxicities and is chiefly composed of mild nausea and vomiting. Acutely occurring and self-limiting loss of vision has not been 
reported in the literature as a potential side effect. We discuss such a case with a transient and self-limiting visual loss in a patient 
on two consecutive courses of the planned CT. We advocate a further in-depth research to find the cause of such an association.
Key words: Gestational trophoblastic neoplasia, Methotrexate, Oculopathy
Tiwari and Suhaib Atypical toxicity in choriocarcinoma chemotherapy
Vol 4 | Issue 6 | Nov - Dec 2018 Indian J Case Reports 469
During the next cycle, again while receiving injection 
leucovorin, she complained of diminution of vision which resolved 
in 15–20 min. A repeat ophthalmic examination, however, did not 
reveal any abnormality. The previous findings of disc edema and 
disc hyperemia were absent and the margin of a cup was also well 
appreciated. The patient responded well to the CT as revealed by 
the beta-HCG levels that reduced to 4.5 mIU/ml. She was doing 
fine without any ocular or systemic symptom/sign at a 6-month 
follow-up.
DISCUSSION
The use of MTX includes a variety of cancerous and non-
cancerous conditions. In the absence of a contraindication, it is the 
medical treatment recommended for tubal ectopic pregnancy and 
constitutes an alternative conservative treatment to laparoscopic 
salpingotomy for non-complicated tubal ectopic pregnancy with 
HCG level <5000 UI/L [6]. It is currently used in gynecology to 
treat disorders arising from trophoblastic tissue, namely ectopic 
pregnancy and GTN [4].
The World Health Organization has stratified GTN into a low-
risk group (score ≤6) intimating single-agent CT and high-risk 
group (score >6) mandating multiagent CT (Table 1) [7]. Single-
agent MTX has revolutionized the treatment of GTN. Previously, 
women with low-risk disease had to undergo hysterectomy, while 
those with high-risk disease inevitably died from the condition. 
MTX has not only replaced surgery as a treatment option but is used 
to cure almost 100% of women with the low-risk disease and up to 
86% of women with high-risk disease in combination CT [4,8,9].
An 8-day multidose MTX protocol with intervening folinic 
acid (to minimize toxicity) was first suggested by Bagshawe and 
Wilde, in 1964 [4]. This regimen remains the first-line treatment 
for low-risk disease and is the most widely used regimen in the 
world. It achieves remission in 90% of low-risk Stage I patients 
and 70% of low-risk Stages II–III patients [4]. The toxicity profile 
of this regimen is low and comprises chiefly of nausea (<15%) 
and vomiting (<5%), and 2% of patients develop mouth ulcers, 
sore eyes, or chest or abdominal pain. Rarely, a life-threatening 
toxicity due to myelosuppression has also been reported in the 
literature [10]. Treatment is continued until the serum β-HCG 
normalizes (<5 IU/L) for at least 3 consecutive weeks [4].
MTX preferentially targets rapidly dividing cells; therefore, 
the hematological, gastrointestinal, and dermatological systems 
are the most likely to display features of toxicity (neutropenia, 
myelosuppression, nausea, vomiting, diarrhea, generalized 
erythema, rash, photosensitivity, and alopecia) [5]. Acute onset, 
short duration, and self-remitting blurring of vision with low-
dose MTX administration have not been reported previously 
to the best of our knowledge. The literature search reveals a 
case report describing a reduced full-field electroretinogram in 
b-wave amplitude in a 13-year-old boy treated with MTX for 
8.5 years [11] while in our case, the patient developed symptoms 
very early. We could not find any literature pertaining to a similar 
scenario as seen in our patient.
CONCLUSION
We postulate that even in low doses, MTX has the potential to 
cause ocular toxicity and appears to be a diagnosis of exclusion. 
Although rare, this is an important consideration to be kept in 
mind while using MTX and warrants further research to find a 
safety threshold for MTX use.
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